Access cutting-edge prostate cancer treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.
Access prostate cancer specialists in Boston at no cost
This study follows strict safety protocols and ethical guidelines
All study-related prostate cancer treatment provided free
This is a three-part study evaluating the safety and efficacy of a PSMA-directed radioantibody (rosopatamab tetraxetan, conjugated to either In-111 or Ac-225). Part 1 will consist of one administration of In-111-rosopatamab tetraxetan to characterize the biodistribution of the radioantibody to target organs and prostate cancer lesions. Participants then will be enrolled into either Part 2 (Dose Optimization) or Part 3 (Dose Escalation and Expansion) depending on their prior treatment history. Pa
Sponsor: Convergent Therapeutics
Check if you qualify for this prostate cancer clinical trial in Boston, MA
If you're searching for prostate cancer treatment options in Boston, MA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.